What is Optinose?
Optinose operates at the intersection of pharmaceutical innovation and specialized patient care. By focusing on the unique needs of patients managed by ENT and allergy specialists, the company has carved out a distinct market position. Headquartered with a dual presence in the United States and Norway, Optinose leverages its research and development capabilities to address unmet clinical needs. The firm's business model is characterized by a commitment to high-barrier-to-entry therapeutic segments, supported by a robust history of private equity and venture capital investment. This strategic focus allows the company to maintain a competitive edge in the specialty pharma landscape, ensuring that its proprietary delivery technologies and therapeutic candidates remain aligned with the evolving requirements of healthcare providers and their patients.
How much funding has Optinose raised?
Optinose has raised a total of $630.7M across 10 funding rounds:
Unspecified
$933K
Private Equity
$48.5M
Series C
$35M
Other Financing Round
$30M
Series D
$37M
Stock Offering
$138M
Debt
$100M
Stock Offering
$52.3M
Debt
$150M
Stock Offering
$39M
Unspecified (2002): $933K with participation from Andromeda Capital
Private Equity (2010): $48.5M led by Avista Capital Partners
Series C (2014): $35M supported by WFD VENTURES, Avista Capital Partners, and Entrepreneurs Fund
Other Financing Round (2015): $30M featuring WFD VENTURES, Entrepreneurs Fund LP, and Avista Capital Partners
Series D (2017): $37M backed by Entrepreneurs Fund, Avista Capital Partners, and Fidelity Management and Research Company
Stock Issuance/Offering (2017): $138M, investors not publicly disclosed
Debt (2018): $100M led by Athyrium Capital Management, LP
Stock Issuance/Offering (2018): $52.3M, investors not publicly disclosed
Debt (2019): $150M featuring Pharmakon Advisors, LP
Stock Issuance/Offering (2019): $39M, investors not publicly disclosed
Key Investors in Optinose
Avista Capital Partners
A private equity firm focused on making influential investments in growth-oriented healthcare, media, and energy companies.
Entrepreneurs Fund
A venture capital member of COFRA Holding that supports the formation and growth of technology-driven global businesses.
WFD VENTURES
An investment firm providing equity financing and industry expertise specifically to medical device and healthcare technology companies.
What's next for Optinose?
Looking ahead, the infusion of capital from recent financing rounds positions Optinose to accelerate its commercialization efforts and expand its therapeutic pipeline. As the company transitions into a more mature phase of its lifecycle, the focus will likely shift toward scaling market access and optimizing the distribution of its specialty products. The continued support from long-term institutional partners suggests a stable trajectory for future growth, with potential for further strategic partnerships or product line extensions. By maintaining its commitment to ENT and allergy innovation, Optinose is well-equipped to navigate the complexities of the pharmaceutical market, leveraging its established infrastructure to drive long-term value for stakeholders and improve patient outcomes in its core therapeutic areas.
See full Optinose company page
